SAVE THE DATE!
The 4th HARMONY General Assembly 2019 is organized on the 26th and 27th September in Florence, Italy.
With the first results in AML, CLL, and MM, our groups in MDS, ALL/Pediatrics, and NHL working full steam ahead, and the increasing number of datasets in the HARMONY Big Data Platform, the 4th HARMONY General Assembly will be the perfect starting point for the second wave of HARMONY research projects.
Join us in this new phase of the project and get engaged in the research-a-thon sessions that we have organised for each of the 7 hematologic malignancies where HARMONY Partners and Associated Members are collaborating. Become an active member in the elaboration of the next research proposals, commit to sharing your data, and start working hand in hand with our group of HARMONY multidisciplinary experts!
- The cooperating mutational pattern of cases showing mutations in classical splicing factors such as SRSF2, SF3B1etc., and investigate in further depths the cohesion factor mutations which are also involved in transcriptional regulation and splicing;
- Differences in mutational patterns with regard to gender differences and performing gender-dependent outcome analyses in defined AML subgroups;
- Mutational profiles of sAML and tAML cases as well as into de novo AML that was primary refractory or showed early relapse.
- Secondary neoplasia in the history of CLL (with or without therapies; CIT or novel therapies);
- Correlation between MRD and outcomes in CLL; validation of establishing UMRD as a relevant primary endpoint in CLL.
- KMT2A (MM) re-arrangements in ALL patients;
- Adult B cell precursors in ALL.
- Event free survival (EFS) as surrogate endpoint for OS to be used in clinical trials. Implement recently modified IWG criteria for response;
- Are patients with isolated monosomy 7 more sensitive to HMAs? (and the effect of cytogenetic alterations on response).
- Specific outcome of patients with TP 53 mutation after HMAs. And other mutations and commutations?
- Outcome of CMML dysplastic (azacitidine) and proliferative (decitabine in clinical trials).
- Incidence and prognostic value of febrile neutropenia and relative treatment/ prophylaxis.
- Characterize features of specific subgroups of patients: long responders, elderly, hypocellular marrow etc
- Evaluation of clonal evolution during/after HMA therapy (for cases with sequential samples).
- HMAs as bridge to transplant : how many cycles? Which kind of response?
- Predictors of initial response duration in patients newly diagnosed with MM.
- Are there specific predictors of patients who relapse early after initial treatment?
- Newly approved novel targeted agents bring both value and complication to treatment selection and sequencing in DLBCL.
- Is there space to improve R-CHOP strategy by adding new drugs, drug combinations or sequences? Some recent attempts have failed, why? Will large scale genetic datasets help to refine first-line treatment strategies?
- Novel therapeutics in R/R DLBCL are needed, we still deal with poor survival outcomes despite salvage chemotherapy with or without SCT in a relevant number of patients.
- High-grade B-cell lymphoma /Double-hit lymphoma (DHL) need new therapeutic approaches: anti BCL2, MYC, or other associated pathways.
- There is limited data on differential therapy by DLBCL subtype.
- DLBCL remains a heterogeneous disease. We need refinements in the understanding of the complex pathogenesis and to improve strategies for treatment choice.
- Is it pcALCL or psALCL? ALCL with uncertain classification regarding primary systemic vs. primary cutaneous ALCL origin. Genetic and biological characterization and impact of treatment approach on outcome.
- What patients benefits from upfront SCT; clinical, biological and genetic stratification.
- Evaluation of surrogate outcomes and related regulatory strategies. From a regulatory point of view, the operating characteristics of the regulatory rules that are based on surrogate endpoints are of high importance to understand the consequences of regulatory decisions based on surrogates and to potentially adjust regulatory rules. Join this working session to help us shaping the next HARMONY research project on regulatory strategies based on surrogate endpoints on AML.
Kindly hosted by our partner Menarini Ricerche, representative of our 53 Partners, 37 Associated Members and Patient Cluster will meet to continue moving forward in topics such as the definition and alignment on HM outcomes and the pathway for patients to get access to the right treatment at the right time.
The General Assembly is a highly valuable annual meeting [only to be attended by the official HARMONY Alliance contacts] both from a substance as from a collaborative perspective.
Receive the latest news. Click here to subscribe!